Margeli A, Kouraklis G, Theocharis S
Department of Clinical Biochemistry, Aghia Sophia Children's Hospital, Athens, Greece.
Angiogenesis. 2003;6(3):165-9. doi: 10.1023/B:AGEN.0000021377.13669.c0.
The peroxisome proliferator activated receptor (PPAR)- gamma ligands have been initially described as important regulators of adipogenic differentiation and glucose homeostasis. Detailed studies in different tissues pointed to the roles of these ligands in cell proliferation and cancer, establishing their anticancer properties against a wide variety of neoplastic cells. The growth of any solid tumor depends on angiogenesis, as tumor vascularization is a vital process for tumor volume increase and its metastatic potential. Recently, the role of PPAR- gamma ligands as potent angiogenesis modulators in vitro and in vivo, has been referred. This review takes into consideration the latest data concerning the participation of PPAR- gamma ligands in the biological mechanisms underlying angiogenesis inhibition (important in anticancer therapy) and the controversy concerning angiogenesis induction (important in non-neoplastic diseases). As inhibition of angiogenesis represents one of the more promising, new approaches to anticancer therapy, PPAR- gamma ligands in addition to their established role as tumor cell cycle modulators could be implicated in future strategies for cancer treatment.
过氧化物酶体增殖物激活受体(PPAR)-γ配体最初被描述为脂肪生成分化和葡萄糖稳态的重要调节因子。在不同组织中的详细研究表明这些配体在细胞增殖和癌症中发挥作用,确立了它们对多种肿瘤细胞的抗癌特性。任何实体瘤的生长都依赖于血管生成,因为肿瘤血管化是肿瘤体积增加及其转移潜能的关键过程。最近,有人提到了PPAR-γ配体在体外和体内作为强效血管生成调节剂的作用。本综述考虑了有关PPAR-γ配体参与血管生成抑制(在抗癌治疗中很重要)的生物学机制的最新数据,以及有关血管生成诱导(在非肿瘤性疾病中很重要)的争议。由于血管生成抑制是抗癌治疗中更有前景的新方法之一,PPAR-γ配体除了作为肿瘤细胞周期调节剂已确立的作用外,还可能参与未来的癌症治疗策略。